Efficacy Trial of a Mobile Application for Fluid Intake Management in Patients Receiving Chronic Hemodialysis Therapy

IF 4.1 Q1 UROLOGY & NEPHROLOGY
Kidney Medicine Pub Date : 2026-08-01 Epub Date: 2026-06-17 DOI:10.1016/j.xkme.2026.101443
Michael Rocco, Marion Rigaud, Carole Ertel, Greg Russell, Juliane Zemdegs, Mariacristina Vecchio
{"title":"Efficacy Trial of a Mobile Application for Fluid Intake Management in Patients Receiving Chronic Hemodialysis Therapy","authors":"Michael Rocco,&nbsp;Marion Rigaud,&nbsp;Carole Ertel,&nbsp;Greg Russell,&nbsp;Juliane Zemdegs,&nbsp;Mariacristina Vecchio","doi":"10.1016/j.xkme.2026.101443","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><div>Increased interdialytic weight gain (IDWG) is associated with increased morbidity and mortality in patients receiving chronic hemodialysis. We evaluated the efficacy of a smartphone-based application (app) designed to support reductions in interdialytic fluid intake.</div></div><div><h3>Study Design</h3><div>Pre–post intervention study.</div></div><div><h3>Setting &amp; Participants</h3><div>Adult patients receiving chronic hemodialysis with mean IDWG &gt;3.5% over a 3-month period were recruited from outpatient hemodialysis units in central North Carolina, United States.</div></div><div><h3>Intervention</h3><div>Participants were trained to use a smartphone-based app that allowed recording fluid intake and incorporated behavioral support features (eg, goal setting, prompts, feedback). The patients were asked to use the app daily during the 8-week active phase of the trial.</div></div><div><h3>Outcomes</h3><div>The primary study outcome was the change in mean IDWG from baseline (before app usage) to the 8-week active phase. Secondary outcomes included app safety and usage. IDWG was also assessed during a 6-month passive phase to monitor for possible long-term behavioral changes.</div></div><div><h3>Results</h3><div>Twenty-three patients completed the 8-week active phase and provided app data. Compared with baseline, mean IDWG for the 3-day interdialytic interval decreased by −0.52 ± 0.24 lb (<em>P</em> = 0.032) during the active phase and −0.86 ± 0.96 lb (<em>P</em> &lt; 0.01) during the passive phase. No safety concerns (defined as &gt;50% increase in IDWG) were observed. During the active phase, app was used on ≥80% of the days by 65% of participants and daily by 26% of participants. Reductions in IDWG were sustained during the passive phase. Correlations between app-recorded fluid intake and IDWG were weak and not statistically significant.</div></div><div><h3>Limitations</h3><div>This uncontrolled pre–post study was subject to selection bias toward more technologically literate and adherent participants, did not meet recruitment targets, and lacked urine output data.</div></div><div><h3>Conclusions</h3><div>Use of a smartphone-based app designed to support fluid intake restriction is feasible and associated with sustained reductions in IDWG among patients receiving chronic hemodialysis, without safety concerns.</div></div><div><h3>Plain-Language Summary</h3><div>Excessive weight gains between hemodialysis sessions increase the risk of hospitalization and death. We developed a smartphone app that allows patients to record their fluid intake on a daily basis. The app also provides practical tips to help limit fluid intake and grants digital rewards when goals are met. We found that, on average, patients gained less weight between dialysis sessions while using the app compared with the period before they used it. These results suggest that smartphones apps that combine fluid intake tracking with behavioral support may help patients better control their fluid intake between dialysis sessions.</div></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"8 8","pages":"Article 101443"},"PeriodicalIF":4.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396856/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059526002050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale & Objective

Increased interdialytic weight gain (IDWG) is associated with increased morbidity and mortality in patients receiving chronic hemodialysis. We evaluated the efficacy of a smartphone-based application (app) designed to support reductions in interdialytic fluid intake.

Study Design

Pre–post intervention study.

Setting & Participants

Adult patients receiving chronic hemodialysis with mean IDWG >3.5% over a 3-month period were recruited from outpatient hemodialysis units in central North Carolina, United States.

Intervention

Participants were trained to use a smartphone-based app that allowed recording fluid intake and incorporated behavioral support features (eg, goal setting, prompts, feedback). The patients were asked to use the app daily during the 8-week active phase of the trial.

Outcomes

The primary study outcome was the change in mean IDWG from baseline (before app usage) to the 8-week active phase. Secondary outcomes included app safety and usage. IDWG was also assessed during a 6-month passive phase to monitor for possible long-term behavioral changes.

Results

Twenty-three patients completed the 8-week active phase and provided app data. Compared with baseline, mean IDWG for the 3-day interdialytic interval decreased by −0.52 ± 0.24 lb (P = 0.032) during the active phase and −0.86 ± 0.96 lb (P < 0.01) during the passive phase. No safety concerns (defined as >50% increase in IDWG) were observed. During the active phase, app was used on ≥80% of the days by 65% of participants and daily by 26% of participants. Reductions in IDWG were sustained during the passive phase. Correlations between app-recorded fluid intake and IDWG were weak and not statistically significant.

Limitations

This uncontrolled pre–post study was subject to selection bias toward more technologically literate and adherent participants, did not meet recruitment targets, and lacked urine output data.

Conclusions

Use of a smartphone-based app designed to support fluid intake restriction is feasible and associated with sustained reductions in IDWG among patients receiving chronic hemodialysis, without safety concerns.

Plain-Language Summary

Excessive weight gains between hemodialysis sessions increase the risk of hospitalization and death. We developed a smartphone app that allows patients to record their fluid intake on a daily basis. The app also provides practical tips to help limit fluid intake and grants digital rewards when goals are met. We found that, on average, patients gained less weight between dialysis sessions while using the app compared with the period before they used it. These results suggest that smartphones apps that combine fluid intake tracking with behavioral support may help patients better control their fluid intake between dialysis sessions.
慢性血液透析患者液体摄入管理移动应用程序的疗效试验
理由与目的:慢性血液透析患者的透析间期体重增加(IDWG)与发病率和死亡率增加相关。我们评估了一种基于智能手机的应用程序(app)的功效,该应用程序旨在支持减少透析间期液体摄入量。研究设计:干预前后研究。环境和参与者:从美国北卡罗来纳州中部的门诊血液透析单位招募接受慢性血液透析的成年患者,平均IDWG bbbb3.5 %,为期3个月。干预:参与者被训练使用一个基于智能手机的应用程序,该应用程序允许记录液体摄入量,并结合行为支持功能(例如,目标设定、提示、反馈)。在为期8周的试验活跃阶段,患者被要求每天使用该应用程序。结果:主要研究结果是平均IDWG从基线(应用程序使用前)到8周活跃期的变化。次要结果包括应用程序安全性和使用情况。在6个月的被动阶段还对IDWG进行了评估,以监测可能的长期行为变化。结果:23例患者完成8周活动期并提供app数据。与基线相比,3天透析间期的平均IDWG在活动期下降-0.52±0.24 lb (P = 0.032),在被动期下降-0.86±0.96 lb (P < 0.01)。未观察到安全问题(定义为IDWG增加50%)。在活动阶段,65%的参与者在≥80%的日子使用app, 26%的参与者每天使用app。在被动阶段,IDWG持续减少。app记录的液体摄入量与IDWG之间的相关性很弱,没有统计学意义。局限性:这项不受控制的前-后研究存在对技术知识和依从性更高的参与者的选择偏倚,没有达到招募目标,并且缺乏尿量数据。结论:使用基于智能手机的应用程序来支持液体摄入限制是可行的,并且与接受慢性血液透析的患者中IDWG的持续减少有关,没有安全问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书